ELAN Q4 2018 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q4 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$799M+6.0% YoY

Gross Profit

$337M42.1% margin

Operating Income

$91M11.3% margin

Net Income

$16M2.1% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

$140M

Free Cash Flow

$79M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$9.0B

Total Liabilities

$3.8B

Stockholders' Equity

$5.2B

Cash & Equivalents

$475M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$799M	$754M	+6.0%
Gross Profit	$337M	$349M	-3.6%
Operating Income	$91M	$30M	+198.7%
Net Income	$16M	-$162M	+110.2%

Revenue Segments

Food Animal Ruminants And Swine

$293M37%

Food Animal Future Protein And Health

$209M26%

Companion Animal Disease Prevention

$201M25%

Companion Animal Therapeutics

$72M9%

Companion Animal Other

$25M3%

Geographic Segments

Non-US

$425M53%

UNITED STATES

$375M47%